Eased Tensions On Korean Peninsula To Fuel Botanical Drug R&D?

Herbal-derived drug development on the Korean peninsula is poised to get an initial boost once the relationship between the North and South improves, although it is uncertain how the possible easing of tensions between the two countries will broadly affect South Korea's pharma sector.

South and North Korea
SOUTH AND NORTH KOREA MULL COOPERATION • Source: shutter stock

The herbal-derived drug sector is set to become an initial beneficiary once South Korea's relationship with North Korea improves, as the South is aiming to make use of its communist neighbor's abundant natural resources by jointly conducting research on natural products and herbal-derived drugs to beef up its global competitiveness in these sectors.

If the latest planned cooperative project is actually launched based on eased tensions on the peninsula, it is poised to help South Korea secure herbal drug materials, which are currently mostly imported and form an important component of medicine in the country

More from Business

More from Scrip

AbbVie On MFN: ‘We Have To Take It Seriously’

 

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.